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Erratum to: ‘Models and impact of patient
and public involvement in studies carried
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Clinical Trials Unit at University College
London: findings from ten case studies’
Annabelle South1*, Bec Hanley1, Mitzy Gafos1, Ben Cromarty1,2, Richard Stephens1,3, Kate Sturgeon1, Karen Scott1,
William J. Cragg1, Conor D. Tweed1, Jacqueline Teera1 and Claire L. Vale1
Erratum
Unfortunately, the original version of this article [1]
contained an error. Box 1 was omitted from the HTML
version however the PDF version is fine and Box 1 can be
seen there. To correct this we have included Box 1 below
and will also be doing an update.
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Box 1 Lessons learnt: the views of researchers and
patient representatives
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Who to involve:
● Enthusiasm for research was considered an essential characteristic for
patient representatives. There was less agreement over what other
skills or attributes were essential.
● Patient representatives who had scientific backgrounds (in a variety of
different areas of science) felt that helped them to adapt to the
language and processes of medical research
● Trial participants can provide unique insights because they are going
through the trial. This may be very valuable.
● Some patient and community organisations can help to match
interested people with research with researchers, based on
their relevant skills and experience and the focus of the
research.
Providing support:
● Examples of support provided by researchers, that PPI representatives
found to be useful include (but are not limited to):
○ Taking time to explain things to patient representatives
○ Helping patient representatives to prepare for meetings
○ Organising visits to trial sites to see how the trial runs
○ Providing a glossary of terms (including study-specific ones) that
may be used.
○ Remembering that patient representatives may be personally
affected by discussions.
○ Helping PPI representatives develop a better understanding of
statistical concepts, especially at the analysis stage.
● Existing patient groups and community organisations can act as a
vital bridge between researchers and patient and/or community
representatives
● Building on existing community structures (such as community
groups, work places or traditional leadership groups) rather than
trying to create new ones can help to encourage community
engagement (see MDP interview notes for more details)
● Having more than one PPI representative on a group or committee is
important because:
○ They can help to support each other
○ It can help with the continuity of involvement, in particular where
the study takes place over a prolonged period of time, or where
there may be high turnover of patient representatives
○ It can help with diversity of involvement, in particular where there
is considerable diversity in the population affected.
Types of involvement
● Integrating PPI at a cross-study or Unit level (e.g. Protocol Review
Committee, or a panel of patient/community representatives to
advise on several studies in a disease area) may facilitate PPI in the
development and early phases of a study.
● It can be helpful to involve people who are already well known and
have strong links to, patient groups/the community, particularly for
involvement in more formal trial committees.
● Involving patients on data monitoring committees can be
helpful, especially where side effects are an issue, as they can
give a patient’s perspective on the balance between risks and
benefits.
● Using a mix of PPI models, i.e. having different types of involvement
at different stages of a trial and with different groups and individuals,
may enhance the potential impacts of PPI.
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